Abstract
High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].
| Original language | English (US) |
|---|---|
| Pages (from-to) | 626-655 |
| Number of pages | 30 |
| Journal | Journal of the National Cancer Institute |
| Volume | 80 |
| Issue number | 9 |
| DOIs | |
| State | Published - Jul 6 1988 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'The role of methotrexate in osteosarcoma'. Together they form a unique fingerprint.
Cite this
Grem, J. L., King, S. A., Wittes, R. E., & Leyland-jones, B. (1988). The role of methotrexate in osteosarcoma. Journal of the National Cancer Institute, 80(9), 626-655. https://doi.org/10.1093/jnci/80.9.626